Innovent Biologics, Inc. (Innovent, 信达生物制药（苏州）有限公司) is a privately held biopharmaceutical company that is dedicated to the development and manufacturing of monoclonal antibodies and other biopharmaceuticals to be marketed in China and elsewhere around the world.
Innovent is funded by the venture arm of Fidelity, which is a major investment firm in the US. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development and manufacture of biologics in the US, Innovent has entered product licensing agreements with well established biopharmaceutical companies to leverage the growing pharmaceutical market in China. Innovent is actively seeking product candidates for in-licensing and co-development.
Innovent has initiated design and construction of a new campus located in Suzhou near Shanghai China. In addition to laboratories and offices, the campus will house our commercial manufacturing plant with 10,000 L bioreactors and our pilot plant to produce clinical testing materials. These plants are designed to comply with international requirements for cGMP as defined by the European EMA and the US FDA. These plants also comply with China SFDA cGMP regulations.
Innovent is seeking qualified staff to lead our process development teams, particularly in cell culture, downstream processing, and analytical methods and also for quality assurance.
信达生物制药（苏州）有限公司是一家致力于研发及生产单克隆抗体药物及其它生物制药产品的生物制药公司。公司的产品主要着眼于中国及全世界市场。
信达生物制药由美国著名的富达基金的风险投资部门创建。公司的创始人和高级管理团队在美国、欧洲和全世界范围内生物产品的研发、生产方面有超过70年的联合工作经验。
信达生物制药已经跟一些著名的生物制药公司达成产品转让协议。公司正在积极寻找可以授权转让及联合开发的候选产品。
信达生物制药生产基地坐落于苏州工业园区生物科技园内，已经进入设计、建设阶段。除了实验室、行政办公室之外，生产基地还包括能容纳10,000升生物反应器的生产车间，生产临床试验材料的中试车间。这些车间完全是根据欧盟EMA及美国FDA cGMP国际标准建立的，同时也符合中国SFDA cGMP标准
